Caution about ketoacidosis, UTIs, and other serious ADRs with the SGLT2s
February 2016
More warnings for the SGLT2 inhibitors (canagliflozin, etc) will increase concerns about their safety.
These "flozins" are popular oral diabetes meds because they have a low risk of hypoglycemia...lead to modest weight loss...and can lower BP.
Plus empagliflozin (Jardiance) has CV benefits including a reduced risk of cardiovascular death and heart failure hospitalizations.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote